Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation
Standard
Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. / Müller, Ingo; Kordowich, Sandra; Holzwarth, Christina; Isensee, Gesa; Lang, Peter; Neunhoeffer, Felix; Dominici, Massimo; Greil, Johann; Handgretinger, Rupert.
in: BLOOD CELL MOL DIS, Jahrgang 40, Nr. 1, 18.09.2007, S. 25-32.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation
AU - Müller, Ingo
AU - Kordowich, Sandra
AU - Holzwarth, Christina
AU - Isensee, Gesa
AU - Lang, Peter
AU - Neunhoeffer, Felix
AU - Dominici, Massimo
AU - Greil, Johann
AU - Handgretinger, Rupert
PY - 2007/9/18
Y1 - 2007/9/18
N2 - Multipotent mesenchymal stromal cells (MSC) have immunomodulatory effects. The aim of this study was to demonstrate safety and feasibility of MSC transfusion in pediatric patients who had undergone allogeneic stem cell transplantation from MMFD, MUD, MMUD and MSD. Patients with posttransplant complications based on deregulated immune effector cells who may benefit from an immunomodulatory effect of MSC had been selected. MSC were isolated from the hematopoietic stem cell donors in five cases and from a third party parental donor in two cases. We transfused ex vivo-expanded MSC in 11 doses into seven pediatric patients. Cell doses were escalated based on availability from 0.4x10(6) to 3.0x10(6) per kg bodyweight No adverse effects were detected with a maximum follow-up of 29 months. One out of three patients showed slight improvement of chronic GVHD. Two patients with severe acute GvHD did not progress to cGvHD. One patient received MSC to stabilize graft function after secondary haploidentical transplantation. One patient recovered from trilineage failure due to severe hemophagocytosis. This is the first case of a pediatric patient treated with MSC for trilineage failure after haploidentical stem cell transplantation from her father. We report the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation. Transfusion of MSC was safe and encouraging improvements in some patients were observed.
AB - Multipotent mesenchymal stromal cells (MSC) have immunomodulatory effects. The aim of this study was to demonstrate safety and feasibility of MSC transfusion in pediatric patients who had undergone allogeneic stem cell transplantation from MMFD, MUD, MMUD and MSD. Patients with posttransplant complications based on deregulated immune effector cells who may benefit from an immunomodulatory effect of MSC had been selected. MSC were isolated from the hematopoietic stem cell donors in five cases and from a third party parental donor in two cases. We transfused ex vivo-expanded MSC in 11 doses into seven pediatric patients. Cell doses were escalated based on availability from 0.4x10(6) to 3.0x10(6) per kg bodyweight No adverse effects were detected with a maximum follow-up of 29 months. One out of three patients showed slight improvement of chronic GVHD. Two patients with severe acute GvHD did not progress to cGvHD. One patient received MSC to stabilize graft function after secondary haploidentical transplantation. One patient recovered from trilineage failure due to severe hemophagocytosis. This is the first case of a pediatric patient treated with MSC for trilineage failure after haploidentical stem cell transplantation from her father. We report the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation. Transfusion of MSC was safe and encouraging improvements in some patients were observed.
KW - Adolescent
KW - Child
KW - Child, Preschool
KW - Female
KW - Graft Rejection
KW - Graft vs Host Disease
KW - Humans
KW - Male
KW - Mesenchymal Stem Cell Transplantation
KW - Mesenchymal Stromal Cells
KW - Multipotent Stem Cells
KW - Peripheral Blood Stem Cell Transplantation
KW - Reoperation
KW - Stromal Cells
KW - Transplantation, Homologous
KW - Treatment Outcome
U2 - 10.1016/j.bcmd.2007.06.021
DO - 10.1016/j.bcmd.2007.06.021
M3 - SCORING: Journal article
C2 - 17869550
VL - 40
SP - 25
EP - 32
JO - BLOOD CELL MOL DIS
JF - BLOOD CELL MOL DIS
SN - 1079-9796
IS - 1
ER -